Literature DB >> 3929968

Extrapyramidal reactions with metoclopramide.

D N Bateman, M D Rawlins, J M Simpson.   

Abstract

The epidemiology of extrapyramidal reactions to metoclopramide was studied by examining reports in the Adverse Reactions Register of the Committee on the Safety of Medicines and comparing these with prescribing figures by general practitioners in the United Kingdom for metoclopramide (Maxolon). In the period 1967-82 there were an estimated 15.9 million prescriptions and 479 reports of extrapyramidal reactions (455 of dystonia-dyskinesia, 20 of parkinsonism, and four of tardive dyskinesia). When corrected for prescribing rates the relative risk of dystonia and dyskinesia was 1.8 in female compared with male patients (95% confidence interval 1.4-2.2). The overall reporting rate for dystonia and dyskinesia was 28.6/million prescriptions but was significantly more common in young adults (p less than 0.0001) and especially girls and women aged 12-19 (190.7 reports/million prescriptions). By contrast parkinsonian reactions were significantly more common in the elderly (p less than 0.0001).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929968      PMCID: PMC1417247          DOI: 10.1136/bmj.291.6500.930

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  12 in total

1.  A survey of drug-induced extrapyramidal reactions.

Authors:  F J AYD
Journal:  JAMA       Date:  1961-03-25       Impact factor: 56.272

2.  Prolactin secretion by metoclopramide in man.

Authors:  S J Judd; L Lazarus; G Smythe
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

3.  Dystonic reactions in children caused by metoclopramide.

Authors:  M Casteels-Van Daele; J Jaeken; P Van der Schueren; P Van den Bon
Journal:  Arch Dis Child       Date:  1970-02       Impact factor: 3.791

4.  Loss of rat striatal dopamine receptors with ageing is selective for D-2 but not D-1 sites: association with increased non-specific binding of the D-1 ligand [3H]piflutixol.

Authors:  K M O'Boyle; J L Waddington
Journal:  Eur J Pharmacol       Date:  1984-10-01       Impact factor: 4.432

5.  Metoclopramide and dystonic reactions in Sardinians.

Authors:  G U Corsini; F Marrosu; G L Gessa
Journal:  Lancet       Date:  1979-06-23       Impact factor: 79.321

6.  Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.

Authors:  J Porter; H Jick
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

7.  Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.

Authors:  D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

8.  Tardive dyskinesia associated with metoclopramide.

Authors:  B E Wiholm; O Mortimer; G Boethius; J E Häggström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

Review 9.  Metoclopramide: a review of its pharmacological properties and clinical use.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  The effect of hyoscine butylbromide on the swallowing of capsules.

Authors:  K S Channer; A Wolinski; B Kaye; J Virjee
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

View more
  52 in total

Review 1.  Acute dystonia induced by drug treatment.

Authors:  P N van Harten; H W Hoek; R S Kahn
Journal:  BMJ       Date:  1999-09-04

Review 2.  Case-population studies in pharmacoepidemiology.

Authors:  Dolors Capellà; Consuelo Pedrós; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Metoclopramide in the treatment of diabetic gastroparesis.

Authors:  Allen Lee; Braden Kuo
Journal:  Expert Rev Endocrinol Metab       Date:  2010

4.  The yellow card: mark II.

Authors:  D H Lawson
Journal:  BMJ       Date:  1990-12-01

Review 5.  Acute dystonic reaction caused by metoclopramide, versus tetanus.

Authors:  Kyra Dingli; Rhoda Morgan; Clifford Leen
Journal:  BMJ       Date:  2007-04-28

6.  Withdrawal effects of metoclopramide.

Authors:  A M Noll; D Pinsky
Journal:  West J Med       Date:  1991-06

7.  A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Authors:  B Chevallier; P Cappelaere; T Splinter; M Fabbro; J L Wendling; L Cals; G Catimel; M Giovannini; D Khayat; P Bastit; N Claverie
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

Review 8.  Susceptibility to adverse drug reactions.

Authors:  Robin Ferner; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2019-07-17       Impact factor: 4.335

9.  The serotonin type 3 receptor antagonist BRL 43694 and nausea and vomiting induced by cisplatin.

Authors:  J Carmichael; B M Cantwell; C M Edwards; W G Rapeport; A L Harris
Journal:  BMJ       Date:  1988-07-09

Review 10.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.